Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$58.77
-0.2%
$58.47
$39.35
$63.33
$119.45B0.4312.12 million shs1.15 million shs
Cerner Co. stock logo
CERN
Cerner
$94.92
$94.92
$69.08
$95.40
$27.92B0.774.00 million shs1,320 shs
Doximity, Inc. stock logo
DOCS
Doximity
$58.52
-3.4%
$65.39
$22.96
$85.21
$10.99B1.341.89 million shs213,242 shs
(LNKD) stock logo
LNKD
(LNKD)
$195.96
$0.00
$98.25
$239.48
N/AN/A2.42 million shsN/A
Microsoft Co. stock logo
MSFT
Microsoft
$384.16
-1.6%
$406.52
$376.91
$468.35
$2.86T0.9219.25 million shs2.51 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$24.93
-0.3%
$26.09
$24.48
$31.54
$141.53B0.6136.70 million shs5.33 million shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
-0.47%-2.48%+1.11%+2.11%+10.60%
Cerner Co. stock logo
CERN
Cerner
0.00%0.00%0.00%0.00%0.00%
Doximity, Inc. stock logo
DOCS
Doximity
-1.51%-3.59%-15.69%+4.86%+124.48%
(LNKD) stock logo
LNKD
(LNKD)
0.00%0.00%0.00%0.00%0.00%
Microsoft Co. stock logo
MSFT
Microsoft
+0.16%+0.97%-1.84%-9.28%-7.32%
Pfizer Inc. stock logo
PFE
Pfizer
-0.56%-4.26%-6.37%-5.89%-9.79%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
3.9242 of 5 stars
1.23.04.24.03.63.30.0
Cerner Co. stock logo
CERN
Cerner
1.5637 of 5 stars
0.00.02.53.90.01.71.3
Doximity, Inc. stock logo
DOCS
Doximity
2.2469 of 5 stars
2.30.00.00.02.44.21.3
(LNKD) stock logo
LNKD
(LNKD)
N/AN/AN/AN/AN/AN/AN/AN/A
Microsoft Co. stock logo
MSFT
Microsoft
4.9474 of 5 stars
4.54.03.32.92.81.71.9
Pfizer Inc. stock logo
PFE
Pfizer
4.9874 of 5 stars
3.33.04.24.23.33.33.1
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
2.32
Hold$57.86-1.55% Downside
Cerner Co. stock logo
CERN
Cerner
0.00
N/AN/AN/A
Doximity, Inc. stock logo
DOCS
Doximity
2.57
Moderate Buy$64.229.75% Upside
(LNKD) stock logo
LNKD
(LNKD)
0.00
N/AN/AN/A
Microsoft Co. stock logo
MSFT
Microsoft
2.93
Moderate Buy$510.5932.91% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.63
Moderate Buy$31.9228.08% Upside

Current Analyst Ratings Breakdown

Latest DOCS, LNKD, BMY, CERN, MSFT, and PFE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/20/2025
Microsoft Co. stock logo
MSFT
Microsoft
Tigress Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$550.00 ➝ $595.00
3/20/2025
Microsoft Co. stock logo
MSFT
Microsoft
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$550.00 ➝ $550.00
3/20/2025
Microsoft Co. stock logo
MSFT
Microsoft
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageSector Outperform$470.00
3/18/2025
Pfizer Inc. stock logo
PFE
Pfizer
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
3/13/2025
Microsoft Co. stock logo
MSFT
Microsoft
DA Davidson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$425.00 ➝ $450.00
3/12/2025
Pfizer Inc. stock logo
PFE
Pfizer
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
3/10/2025
Pfizer Inc. stock logo
PFE
Pfizer
Hsbc Global Res
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
3/7/2025
Microsoft Co. stock logo
MSFT
Microsoft
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$515.00 ➝ $475.00
2/10/2025
Doximity, Inc. stock logo
DOCS
Doximity
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$55.00 ➝ $65.00
2/10/2025
Doximity, Inc. stock logo
DOCS
Doximity
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$58.00 ➝ $80.00
2/10/2025
Pfizer Inc. stock logo
PFE
Pfizer
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$33.00 ➝ $33.00
(Data available from 3/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$48.30B2.47$6.20 per share9.48$8.08 per share7.27
Cerner Co. stock logo
CERN
Cerner
$5.76B4.84$5.37 per share17.69$12.56 per share7.56
Doximity, Inc. stock logo
DOCS
Doximity
$550.17M19.86$0.72 per share81.32$5.52 per share10.60
(LNKD) stock logo
LNKD
(LNKD)
N/AN/AN/AN/AN/AN/A
Microsoft Co. stock logo
MSFT
Microsoft
$261.80B10.91$13.72 per share28.01$40.72 per share9.43
Pfizer Inc. stock logo
PFE
Pfizer
$63.63B2.22$3.91 per share6.38$15.81 per share1.58
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
-$8.95B-$4.42N/A9.652.07-18.53%13.93%2.46%4/24/2025 (Estimated)
Cerner Co. stock logo
CERN
Cerner
$555.60M$1.9947.7027.432.3710.15%22.86%11.75%N/A
Doximity, Inc. stock logo
DOCS
Doximity
$147.58M$1.0058.8554.694.1036.60%21.75%18.64%N/A
(LNKD) stock logo
LNKD
(LNKD)
N/AN/A0.00N/AN/AN/AN/AN/A
Microsoft Co. stock logo
MSFT
Microsoft
$88.14B$12.4230.9626.132.2135.43%33.36%18.07%4/24/2025 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$8.03B$1.4117.708.230.6412.62%19.47%8.09%4/29/2025 (Estimated)

Latest DOCS, LNKD, BMY, CERN, MSFT, and PFE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/24/2025N/A
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$1.55N/AN/AN/A$10.77 billionN/A
4/24/2025N/A
Microsoft Co. stock logo
MSFT
Microsoft
$3.20N/AN/AN/A$68.54 billionN/A
2/6/2025Q4 2024
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$1.47$1.67+$0.20$0.04$11.57 billionN/A
2/4/2025Q4 2024
Pfizer Inc. stock logo
PFE
Pfizer
$0.48$0.63+$0.15$0.07$17.26 billion$17.76 billion
1/29/2025Q2 2025
Microsoft Co. stock logo
MSFT
Microsoft
$3.15$3.23+$0.08$3.23$68.86 billionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$2.484.22%+6.38%N/A 17 Years
Cerner Co. stock logo
CERN
Cerner
$1.081.14%-20.63%54.27%N/A
Doximity, Inc. stock logo
DOCS
Doximity
N/AN/AN/AN/AN/A
(LNKD) stock logo
LNKD
(LNKD)
N/AN/AN/AN/AN/A
Microsoft Co. stock logo
MSFT
Microsoft
$3.320.86%+10.22%26.73%23 Years
Pfizer Inc. stock logo
PFE
Pfizer
$1.726.90%+2.50%121.99%16 Years

Latest DOCS, LNKD, BMY, CERN, MSFT, and PFE Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
3/11/2025
Microsoft Co. stock logo
MSFT
Microsoft
quarterly$0.830.87%5/15/20255/15/20256/12/2025
3/3/2025
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
quarterly$0.624.14%4/4/20254/4/20255/1/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
2.90
1.25
1.15
Cerner Co. stock logo
CERN
Cerner
0.41
1.79
1.77
Doximity, Inc. stock logo
DOCS
Doximity
N/A
8.74
8.74
(LNKD) stock logo
LNKD
(LNKD)
N/AN/AN/A
Microsoft Co. stock logo
MSFT
Microsoft
0.13
1.35
1.34
Pfizer Inc. stock logo
PFE
Pfizer
0.63
1.00
0.73

Institutional Ownership

CompanyInstitutional Ownership
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
76.41%
Cerner Co. stock logo
CERN
Cerner
82.23%
Doximity, Inc. stock logo
DOCS
Doximity
87.19%
(LNKD) stock logo
LNKD
(LNKD)
63.98%
Microsoft Co. stock logo
MSFT
Microsoft
71.13%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%

Insider Ownership

CompanyInsider Ownership
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
0.09%
Cerner Co. stock logo
CERN
Cerner
0.12%
Doximity, Inc. stock logo
DOCS
Doximity
37.40%
(LNKD) stock logo
LNKD
(LNKD)
12.72%
Microsoft Co. stock logo
MSFT
Microsoft
0.03%
Pfizer Inc. stock logo
PFE
Pfizer
0.06%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
34,3002.03 billion2.03 billionOptionable
Cerner Co. stock logo
CERN
Cerner
25,150294.10 million293.75 millionOptionable
Doximity, Inc. stock logo
DOCS
Doximity
890186.69 million116.87 millionNot Optionable
(LNKD) stock logo
LNKD
(LNKD)
N/AN/AN/AOptionable
Microsoft Co. stock logo
MSFT
Microsoft
228,0007.43 billion7.43 billionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
83,0005.67 billion5.66 billionOptionable

Recent News About These Companies

Pfizer: Value Play or Past Its Prime?
WSJ report of probe to have limited impact on Pfizer, says Citi
Pfizer Inc. stock logo
Pfizer (NYSE:PFE) Trading Down 0.2% - What's Next?
U.S. prosecutors look into claim Pfizer delayed vaccine news, WSJ says
Why Pfizer Is My Largest Healthcare Position

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Bristol-Myers Squibb stock logo

Bristol-Myers Squibb NYSE:BMY

$58.77 -0.13 (-0.22%)
As of 10:35 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Cerner stock logo

Cerner NASDAQ:CERN

Cerner Corporation, together with its subsidiaries, provides health care information technology solutions and tech-enabled services in the United States and internationally. It offers Cerner Millennium architecture, a person-centric computing framework, which includes clinical, financial, and management information systems that allow providers to access an individual's electronic health record (EHR) at the point of care, and organizes and delivers information for physicians, nurses, laboratory technicians, pharmacists, front- and back-office professionals, and consumers. The company also provides HealtheIntent platform, a cloud-based platform to aggregate, transform, and reconcile data across the continuum of care; and CareAware, an EHR agnostic platform that facilitates connectivity of health care devices to EHRs. In addition, it offers a portfolio of clinical and financial healthcare information technology solutions, as well as departmental and care coordination solutions. Further, the company provides tech-enabled services, such as implementation and training, remote hosting, application management, revenue cycle, support and maintenance, health care data analysis, real-world evidence, clinical process optimization, transaction processing, employer health centers, and data-driven services; and complementary hardware and devices for third parties. It serves integrated delivery networks, physician groups and networks, managed care organizations, hospitals, medical centers, free-standing reference laboratories, home health agencies, blood banks, imaging centers, pharmacies, pharmaceutical manufacturers, employers, governments, and public health organizations. The company was founded in 1979 and is headquartered in North Kansas City, Missouri.

Doximity stock logo

Doximity NASDAQ:DOCS

$58.52 -2.03 (-3.35%)
As of 10:35 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Doximity, Inc. operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers. It primarily serves pharmaceutical manufacturers and healthcare systems. The company was formerly known as 3MD Communications, Inc. and changed its name to Doximity, Inc. in June 2010. Doximity, Inc. was incorporated in 2010 and is headquartered in San Francisco, California.

(LNKD) stock logo

(LNKD) NYSE:LNKD

LinkedIn Corporation (LinkedIn) is a professional network on the Internet with approximately 400 million members in over 200 countries and territories. The Company provides the majority of its products at no cost to its members. It offers approximately three product lines: Talent Solutions, which includes Hiring, and Learning and Development; Marketing Solutions and Premium Subscriptions. Its products are sold through approximately two channels, an offline field sales organization, which engages with both large and small enterprise customers, as well as an online, self-serve channel, which includes enterprise customers and individual members purchasing subscriptions. Its solutions include Free Solutions and Monetized Solutions. Its Free Solutions include Stay Connected and Informed, and Advance My Career. The Company's Monetized Solutions include Talent Solutions, which includes Hiring, and Learning and Development, Marketing Solutions and Premium Subscriptions.

Microsoft stock logo

Microsoft NASDAQ:MSFT

$384.16 -6.42 (-1.64%)
As of 10:35 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Microsoft Corporation develops and supports software, services, devices and solutions worldwide. The Productivity and Business Processes segment offers office, exchange, SharePoint, Microsoft Teams, office 365 Security and Compliance, Microsoft viva, and Microsoft 365 copilot; and office consumer services, such as Microsoft 365 consumer subscriptions, Office licensed on-premises, and other office services. This segment also provides LinkedIn; and dynamics business solutions, including Dynamics 365, a set of intelligent, cloud-based applications across ERP, CRM, power apps, and power automate; and on-premises ERP and CRM applications. The Intelligent Cloud segment offers server products and cloud services, such as azure and other cloud services; SQL and windows server, visual studio, system center, and related client access licenses, as well as nuance and GitHub; and enterprise services including enterprise support services, industry solutions, and nuance professional services. The More Personal Computing segment offers Windows, including windows OEM licensing and other non-volume licensing of the Windows operating system; Windows commercial comprising volume licensing of the Windows operating system, windows cloud services, and other Windows commercial offerings; patent licensing; and windows Internet of Things; and devices, such as surface, HoloLens, and PC accessories. Additionally, this segment provides gaming, which includes Xbox hardware and content, and first- and third-party content; Xbox game pass and other subscriptions, cloud gaming, advertising, third-party disc royalties, and other cloud services; and search and news advertising, which includes Bing, Microsoft News and Edge, and third-party affiliates. The company sells its products through OEMs, distributors, and resellers; and directly through digital marketplaces, online, and retail stores. The company was founded in 1975 and is headquartered in Redmond, Washington.

Pfizer stock logo

Pfizer NYSE:PFE

$24.92 -0.09 (-0.34%)
As of 10:35 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.